Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome

Rafraf, Maryam; Mohammadi, Elahe; Asghari‐Jafarabadi, Mohammad; Farzadi, Laya

doi:10.1080/07315724.2012.10720443

Cited by 60 publications

(51 citation statements)

References 52 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dietary factors, including anti-inflammatory foods may have a key role in improving metabolic disorders of PCOS [7]. The beneficial effects of omega-3 fatty acids from flaxseed oil on insulin resistance, inflammation and oxidative stress have previously reported in few studies.…”

Section: The Effects Of Flaxseed Oil Omega-3 Fatty Acids Supplementatmentioning

confidence: 99%

The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

Mirmasoumi

Fazilati

Foroozanfard

et al. 2017

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

Section: The Effects Of Flaxseed Oil Omega-3 Fatty Acids Supplementatmentioning

confidence: 99%

The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

Mirmasoumi

Fazilati

Foroozanfard

et al. 2017

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…Women with polycystic ovarian syndrome and BMI between 25 and 40 kg/m 2 , however, exhibited no significant changes in BMI after supplementation for 8 weeks [60]. The period of treatment in this study may not be long enough to observe significant anthropometric changes after omega-3 administration with no other associated instruction or intervention.…”

Section: Discussionmentioning

confidence: 91%

Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: study protocol for a randomized controlled trial

Silva

Souza

et al. 2013

Trials

View full text Add to dashboard Cite

BackgroundChronic chagasic cardiomyopathy is an inflammatory disease that occurs in approximately 30% of patients infected by the protozoan Trypanosoma cruzi, and it has a profile of high morbidity and mortality. The worst prognosis and the progression of this cardiomyopathy are associated with an exacerbated immune response and the production of proinflammatory cytokines, which also occur in other cardiomyopathies. Some nutrients, including omega-3 polyunsaturated fatty acids (PUFAs), promote the inhibition and/or stimulation of cytokine production. The objective of this trial is to study the effects of omega-3 PUFA supplementation on the inflammatory response and lipid profile in patients with chronic chagasic cardiomyopathy.Methods/DesignThis is a parallel, randomized, placebo-controlled, double-blind clinical trial with 40 patients that will be conducted at a reference unit for Chagas disease patients, where the patients will be selected. The study will include patients with chronic chagasic cardiomyopathy who are 18 years of age or older. The exclusion criteria are (a) ongoing diarrheal disease, (b) inflammatory bowel disease, (c) diabetes or other endocrine disease, (d) use of fibrates, niacin, or statins, (e) use of anti-inflammatory drugs, (f) pregnant and lactating women, (g) use of vitamin, mineral, or omega-3 supplementation during the previous 30 days, (h) hospital admission during the study, and (i) other associated cardiomyopathies. The intervention will be treatment with omega-3 PUFAs at a dose of 3 g/day for 8 weeks, compared to placebo (corn oil). The primary endpoints will be the concentrations of inflammatory markers (interleukin (IL)-1, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)α, interferon (IFN)γ, and transforming growth factor (TGF)β). Secondary endpoints will be the fasting glucose, lipid, and anthropometric profiles. For statistical analysis, we plan to run either a t test or Wilcoxon test (numerical variables) and Pearson’s χ2 or Fisher’s exact test (categorical data), as appropriate.DiscussionEvidence suggests that the anti-inflammatory action of omega-3 PUFAs may have beneficial effects on chronic chagasic cardiomyopathy, as shown for other cardiomyopathies, due to improved control of the inflammatory response. At the end of the study, we predict that patients will have lower inflammatory markers and an improved metabolic and anthropometric profile.Trial registrationCurrent Controlled Trials NCT01863576

show abstract

“…which pointed out toward insignificant effects of omega-3 fatty acid therapy on anthropometrics profile. [38] Therapy with omega-3 fatty acid in patients with CAD led to significant increases in adiponectin serum levels compared to control with significant improvement in HOMA-IR, HOMA-β, insulin levels, and fasting blood glucose, these findings were inconsistent with Yamamoto et al . results which revealed that administration of omega-3 fatty acid produced significant anti-inflammatory effects in patients with CAD associated with hyperlipidemia through an increase in adiponectin serum levels.…”

Section: Discussionmentioning

confidence: 99%

Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile

Al-Kuraishy¹,

Al-Gareeb²

2017

J Basic Clin Pharma

View full text Add to dashboard Cite

Background:Adiponectin is an important adipocyte-related protein that has been postulated to participate in prevention of the development of metabolic syndrome. The relationship between adiponectin serum levels and risk of coronary artery disease (CAD) has been widely investigated and remains controversial. The aim of the present study was to evaluate the effects of rosuvastatin and/or omega-3 fatty acid on adiponectin serum levels in patients with insulin resistance (IR) and CAD.Patients and Methods:This study involved 87 patients with CADs and IR of different etiology, the patients were divided into three groups; 24 patients on treatment with rosuvastatin, 22 patients on treatment with omega-3 fatty acid, 23 patients on treatment with omega-3 fatty acid and rosuvastatin, 18 patients were not previously or currently treated with either rosuvastatin or omega-3 fatty acid, those regarded as control patients. Anthropometric measures, adiponectin serum levels, and other biochemical parameters were assessed in each treated group.Results:Rosuvastatin therapy leads to a significant elevation in adiponectin serum levels from 4.1 ± 0.99 ng/mL to 6.76 ± 1.03 ng/mL compared to control P < 0.01. Omega-3 fatty acid therapy leads to a significant elevation in adiponectin serum levels from 4.1 ± 0.99 ng/mL to 6.11 ± 1.29 ng/mL compared to control P < 0.01. Rosuvastatin plus omega-3 fatty acid therapy lead to a significant elevation in adiponectin serum levels from 4.1 ± 0.99 ng/mL to 7.99 ± 1.76 ng/mL compared to control P < 0.01.Conclusions:Rosuvastatin and/or omega-3 fatty acid lead to significant cardiometabolic protection through an increment in adiponectin serum levels.

show abstract

Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome

Abstract: Omega-3 fatty acids improved insulin sensitivity in PCOS patients. This beneficial effect was not associated with alteration in anthropometric measurements and serum visfatin levels.

Cited by 60 publications

References 52 publications

The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: study protocol for a randomized controlled trial

Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile

Contact Info

Product

Resources

About